Corporate Presentation
November 2021
Forward-Looking Statements
This presentation contains forward-looking statements regarding our current expectations.These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi,CAR-Treg and other technologies to develop safe and effective therapies, the potential for us to benefit and earn milestone and royalty payments from our collaborations and the timing of such benefits and payments, our financial resources and expectations, our revised 2021 financial guidance, plans and timelines for opening manufacturing facilities, plans and timelines for us and our collaborators to enroll patients in and conduct clinical trials and present clinical data and other statements that are not historical fact.These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Our actual results may differ materially and adversely from those expressed. Factors that could cause actual results to differ include, without limitation, risks and uncertainties related to the evolving COVID-19 pandemic and its impact on the global business environment, healthcare systems and business and operations of us and our collaborators, including the initiation and operation of clinical trials; the research and development process; the uncertain timing and unpredictable results of clinical trials, including whether initial clinical trial data will be representative of final clinical trial data and whether final clinical trial data will validate the safety, efficacy and durability of product candidates; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates; unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by us and our collaborators; the potential for us or our collaborators to breach or terminate collaboration agreements; the potential for us to fail to realize our expected benefits of our collaborations; and the uncertainty of our future capital requirements, financial performance and results.There can be no assurance that we and our collaborators will be able to develop commercially viable products.These risks and uncertainties are described more fully in our Annual Report on Form 10-K for the year ended December 31, 2020 as supplemented by our Quarterly Report on Form 10-Q ended September 30, 2021. Forward-looking statements contained in this presentation speak only as of the date hereof, and we undertake no duty to update such information except as required under applicable law.This presentation concerns investigational product candidates that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by any regulatory agency.They are currently limited to investigational use, and no representations are made as to their safety or efficacy for the purposes for which they are being investigated.Any discussions of safety or efficacy are only in reference to the specific results presented here and may not be indicative of an ultimate finding of safety or efficacy by regulatory agencies.
2
Leading Genomic Medicines into the Clinic
We are a genomic medicines company committed to translating ground-breaking science
into medicines that transform the lives of patients with serious disease
Novel | Clinical-stage | In-house |
Science | Programs | Manufacturing |
3
Robust Set of Genomic Medicines Designed to Address Rare Disease, CNS, Oncology and Autoimmune Indications
Phase 3
Hemophilia A | Gene therapy | |
Giroctogene | ||
Cell therapy | ||
fitelparvovec | ||
Genome engineering
Phase 1/2
Fabry Disease | Renal Transplant | Sickle Cell | |||||||||
Isaralgagene | TX200 | Disease | |||||||||
civaparvovec | SAR445136 | ||||||||||
Preclinical
Inflammatory | Renal Transplant | Multiple | Prion | Neurology | ||||||||||||||
Bowel Disease | (Allogeneic) | Sclerosis | Undisclosed | |||||||||||||||
Oncology | Oncology | Neuro- | ALS/FTD | Huntington's |
KITE-037 | Undisclosed | developmental | Disease | |
Disorders | TAK-686 | |||
a-Synuclein | Tauopathies | Neurology | Neurology |
ST-502 | ST-501 | DMI | Undisclosed |
4
Delivering on our 2021 Catalysts
Fabry Disease | Renal Transplant | Complete | ||||||||||||||
(isaralgagene civaparvovec, or ST-920) | (TX200) | Manufacturing Sites | ||||||||||||||
Shared preliminary Ph 1/2 data; | First patient enrolled in | Completed in-house cell therapy | ||||||||||||||
fifth patient dosed | Ph 1/2 study | manufacturing facility in Brisbane | ||||||||||||||
Ph 3 planning initiated | headquarters | |||||||||||||||
Sickle Cell Disease | Hemophilia A | |||||||||
(SAR445136) | (giroctocogene fitelparvovec) | |||||||||
Initial Ph 1/2 results at ASH 2021 | Updated follow-up Ph 1/2 data | |||||||||
Clinical program is advancing | at ASH 2021 | |||||||||
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Sangamo Therapeutics Inc. published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 13:14:07 UTC.